Security Snapshot

Xenon Pharmaceuticals Inc. - Common Shares (XENE) Institutional Ownership

CUSIP: 98420N105

13F Institutional Holders and Ownership History from Q4 2014 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

288

Shares (Excl. Options)

100,223,938

Price

$58.15

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+15,880,970
Value change
+$955,191,305
Number of holders
288
Issuer context Who this page is about. 3 identity fields
Shares outstanding
92,799,600
SEC-reported price per share
$57.09
Insider filing price
$57.09
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • XENE - Xenon Pharmaceuticals Inc. - Common Shares is tracked under CUSIP 98420N105.
  • 288 institutions reported positions in Q1 2026.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 245 to 288 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $3,783,396,815 to $5,803,222,428.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 288 institutions filings for Q1 2026.

Open SEC evidence

Security key

98420N105

Latest holder period

Q1 2026

13F holders

288

13D/G owners

6

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
6
Security
XENE
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 12% +12% $277,261,485 +$30,579,986 8,824,363 +12% FMR LLC 30 Jun 2025
Avoro Capital Advisors LLC 6.3% $328,466,622 5,777,777 Avoro Capital Advisors LLC 31 Mar 2026
WELLINGTON MANAGEMENT GROUP LLP 6.2% +113% $213,557,395 +$116,084,607 4,764,779 +119% Wellington Management Group LLP 31 Dec 2025
BlackRock, Inc. 6.2% $148,914,864 4,757,709 BlackRock, Inc. 30 Jun 2025
DRIEHAUS CAPITAL MANAGEMENT LLC 4.9% $255,350,473 4,491,653 DRIEHAUS CAPITAL MANAGEMENT LLC 31 Dec 2025
JANUS HENDERSON GROUP PLC 4.5% -12% $237,404,577 +$13,194,714 4,175,982 +5.9% JANUS HENDERSON GROUP PLC 31 Mar 2026

As of 31 Mar 2026, 288 institutional investors reported holding 100,223,938 shares of Xenon Pharmaceuticals Inc. - Common Shares (XENE). This represents 108% of the company’s total 92,799,600 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
74%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 12% 10,818,491 +21% 0.03% $629,095,252
Avoro Capital Advisors LLC 6.2% 5,777,777 +6.5% 3.3% $335,977,733
BlackRock, Inc. 6.1% 5,640,118 +11% 0.01% $327,972,862
WELLINGTON MANAGEMENT GROUP LLP 5.2% 4,829,641 +1.4% 0.05% $280,843,625
Driehaus Capital Management LLC 4.8% 4,491,653 -1% 1.9% $261,189,622
Polar Capital Holdings Plc 4.7% 4,405,312 +79% 1.1% $256,168,893
JANUS HENDERSON GROUP PLC 4.5% 4,175,982 +2.3% 0.12% $242,858,453
Capital International Investors 2.9% 2,674,727 -22% 0.04% $155,535,375
CITADEL ADVISORS LLC 2.9% 2,652,990 +101% 0.11% $154,271,368
JPMORGAN CHASE & CO 2.1% 1,923,610 +29% 0.01% $106,856,563
STATE STREET CORP 1.9% 1,720,533 +15% 0% $100,048,994
Affinity Asset Advisors, LLC 1.8% 1,675,000 +34% 5.7% $97,401,250
DEERFIELD MANAGEMENT COMPANY, L.P. 1.7% 1,615,696 +198% 1.1% $93,952,722
Holocene Advisors, LP 1.6% 1,518,686 +18% 0.21% $88,311,591
ALLIANCEBERNSTEIN L.P. 1.5% 1,403,297 -12% 0.02% $62,895,772
WESTFIELD CAPITAL MANAGEMENT CO LP 1.5% 1,401,483 +14% 0.34% $81,496,236
Caligan Partners LP 1.5% 1,393,027 +153% 5.7% $81,004,520
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.4% 1,342,028 +27% 0.09% $78,038,929
BRAIDWELL LP 1.4% 1,338,452 -27% 2.6% $77,830,984
PRICE T ROWE ASSOCIATES INC /MD/ 1.4% 1,329,591 +54% 0.01% $77,317,000
JENNISON ASSOCIATES LLC 1.4% 1,318,814 +2.1% 0.05% $76,689,035
Siren, L.L.C. 1.4% 1,318,564 +62% 2.1% $76,674,497
Alyeska Investment Group, L.P. 1.4% 1,299,469 0.21% $75,564,122
FRANKLIN RESOURCES INC 1.4% 1,280,577 +69% 0.02% $74,465,566
GEODE CAPITAL MANAGEMENT, LLC 1.2% 1,092,932 +15% 0% $63,545,024

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
46
Latest
Q1 2026
Rows shown
1-25 of 46
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 100,223,938 $5,803,222,428 +$955,191,305 $58.15 288
2025 Q4 84,413,479 $3,783,396,815 -$19,907,308 $44.82 245
2025 Q3 84,320,819 $3,385,181,214 +$50,763,750 $40.15 218
2025 Q2 83,131,091 $2,602,180,922 +$191,395,540 $31.30 206
2025 Q1 76,712,560 $2,576,157,111 +$10,187,791 $33.55 206
2024 Q4 76,301,942 $2,990,887,419 +$29,910,038 $39.20 209
2024 Q3 74,889,394 $2,949,541,361 +$275,979 $39.37 202
2024 Q2 74,169,549 $2,891,734,051 +$25,968,930 $38.99 212
2024 Q1 73,488,096 $3,163,931,600 +$66,663,770 $43.05 220
2023 Q4 72,058,517 $3,319,081,625 +$473,994,183 $46.06 204
2023 Q3 61,366,625 $2,096,353,515 +$8,680,142 $34.16 180
2023 Q2 61,306,738 $2,360,645,061 +$10,880,022 $38.50 173
2023 Q1 61,134,066 $2,185,894,799 +$24,625,634 $35.79 161
2022 Q4 60,466,775 $2,384,173,156 +$38,699,727 $39.43 157
2022 Q3 57,955,532 $2,092,174,527 +$39,481,459 $36.10 151
2022 Q2 57,007,759 $1,734,195,451 +$237,069,658 $30.42 149
2022 Q1 49,043,946 $1,499,284,580 +$44,953,028 $30.57 128
2021 Q4 47,689,350 $1,489,826,062 +$453,547,589 $31.24 129
2021 Q3 34,071,867 $521,082,671 +$347,889 $15.28 113
2021 Q2 33,296,183 $619,964,580 +$2,566,015 $18.62 99
2021 Q1 32,964,044 $590,006,963 +$88,828,095 $17.90 88
2020 Q4 28,020,659 $430,912,842 -$1,905,185 $15.38 79
2020 Q3 27,927,587 $309,203,900 -$546,988 $11.07 79
2020 Q2 27,956,934 $350,580,052 +$8,434,389 $12.54 78
2020 Q1 27,692,215 $313,869,842 +$101,491,596 $11.34 69
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .